Received Feb 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | LA |
pain at injection site for days; night shivers; lethargic; possible fever; Fatigue; weakness; This non-serious case was reported by a non-health professional via call center representative and described the occurrence of injection site pain in a 70-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. On 12-FEB-2026, the patient received the 1st dose of Shingrix (left deltoid). On 13-FEB-2026, 1 days after receiving Shingrix, the patient experienced injection site pain (Verbatim: pain at injection site for days), shivers (Verbatim: night shivers), lethargy (Verbatim: lethargic), fever (Verbatim: possible fever), fatigue (Verbatim: Fatigue) and weakness (Verbatim: weakness). The outcome of the injection site pain, shivers, lethargy, fever, fatigue and weakness were unknown. It was unknown if the reporter considered the injection site pain, shivers, lethargy, fever, fatigue and weakness to be related to Shingrix. It was unknown if the company considered the injection site pain, shivers, lethargy, fever, fatigue and weakness to be related to Shingrix. Additional Information: GSK receipt date 15-FEB-2026 The batch number was not provided, and we are unable to contact the reporter.